SCHEMBL2145870

SCHEMBL2145870

COC(=O)c1ccc(OCCn2cnc(C(=O)O)c2O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.57
MAPT P10636 4/20 0.55
RAB9A P51151 2/20 0.53
KDM4E B2RXH2 3/20 0.52
SMN1; SMN2 Q16637 4/20 0.46
HTT P42858 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
TSHR P16473 2/20 0.46
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
ALDH1A1 P00352 2/20 0.44
NPC1 O15118 1/20 0.44
TBXAS1 P24557 2/20 0.43
LMNA P02545 2/20 0.43
GAA P10253 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
USP2 O75604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2145517 0.89 MAPK1 (0.56) MAPK1MAPTRAB9AKDM4ESMN1; SMN2
SCHEMBL2145585 0.87 MAPK1 (0.54) MAPK1MAPTRAB9AKDM4ESMN1; SMN2
SCHEMBL2145861 0.83 L3MBTL1 (0.52) RAB9ASMN1; SMN2HTTL3MBTL1TSHR
SCHEMBL2145878 0.82 RXFP1 (0.48) RAB9AKDM4ESMN1; SMN2HTTMEN1
SCHEMBL2145351 0.80 NSD2 (0.49) MAPTALDH1A1TBXAS1
SCHEMBL2145709 0.80 TBXAS1 (0.51) MAPK1KDM4ESMN1; SMN2HTTL3MBTL1
SCHEMBL2146120 0.78 MAPK1 (0.52) MAPK1MAPTRAB9AKDM4ESMN1; SMN2
SCHEMBL2145896 0.77 MAPK1 (0.59) MAPK1MAPTRAB9AKDM4ESMN1; SMN2
SCHEMBL2145589 0.77 MAPT (0.50) MAPK1MAPTRAB9AKDM4ESMN1; SMN2
SCHEMBL2146056 0.77 MAPK1 (0.51) MAPK1MAPTRAB9AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040702-B1 USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM MERCK PATENT GMBH (DE) 2011-07-27 EP claimed
US-8329738-B2 Use of AMPK-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2012-12-11 US disclosed
US-20090253764-A1 USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM MERCK PATENT GESELLSCHAFT (DE) 2009-10-08 US disclosed
EP-2040702-A1 USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Merck Patent GmbH (DE) 2009-04-01 EP disclosed
WO-2008006432-A1 USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM MERCK PATENT GMBH (DE) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253764-A1 USE OF AMPK-ACTIVATING IMIDAZOLE DERIVATIVES, PREPARATION PROCESS THEREFOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PRKAG1, PRKAB1, PRKAG2 MAPK1 356/4885MAPT 3516/4885RAB9A 2518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.